Welcome to our dedicated page for Vistagen Therapeutics SEC filings (Ticker: VTGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing shouldn’t feel like decoding lab notes. Vistagen Therapeutics’ SEC documents run deep with neuroscience data, stem-cell platform details, and pivotal trial timelines—critical facts that can overwhelm even seasoned analysts.
Our platform solves that problem in three steps. First, real-time alerts surface every Vistagen Therapeutics insider trading Form 4 transactions notice, so you can track executive stock moves as they happen. Second, AI-powered summaries turn the 200-page Vistagen Therapeutics annual report 10-K simplified and each Vistagen Therapeutics quarterly earnings report 10-Q filing into a few clear paragraphs, highlighting cash runway, R&D spend, and key pipeline milestones. Third, expert context links each disclosure to what matters for an R&D-heavy business—whether it’s a licensing update in an 8-K material events explained alert or voting matters in the Vistagen Therapeutics proxy statement executive compensation section.
- Instant dashboards for Vistagen Therapeutics Form 4 insider transactions real-time
- AI commentary that answers common questions like “What does this toxicology update mean?” or “How do I read Vistagen Therapeutics SEC filings explained simply?”
- Side-by-side metrics to speed up Vistagen Therapeutics earnings report filing analysis
Whether you’re comparing segment spend across quarters or monitoring Vistagen Therapeutics executive stock transactions Form 4, Stock Titan turns raw disclosures into actionable intelligence—so you spend minutes, not hours, understanding Vistagen’s next scientific milestone.
Great Point Partners and two principals report beneficial ownership of 2,055,834 shares of Vistagen Therapeutics (VTGN), representing 6.59% of the outstanding common stock. The reported interest consists of warrants exercisable into common stock and is calculated using 29,157,733 shares outstanding as reported by the issuer.
The filing is a joint Schedule 13G/A by Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl, each disclosing shared voting and dispositive power over 2,055,834 shares. The warrants contain a Beneficial Ownership Cap that limits exercise so the holder would not exceed 9.99% ownership, and the reporting persons disclaim beneficial ownership of underlying shares except to the extent of pecuniary interest.
Vistagen Therapeutics, Inc. (VTGN) filed a Form 4 on 25-Jun-2025 detailing an equity award to its newly appointed Chief Corporate Development Officer, Elissa S. Cote. On 23-Jun-2025 Ms. Cote received 150,000 stock options with an exercise price of $1.96 per share and an expiration date of 23-Jun-2035. The transaction is coded “A,” indicating an acquisition at no cost to the insider.
The options vest 25 % on 23-Jun-2026, with the remaining 75 % vesting in equal monthly installments over the subsequent 36 months, resulting in full vesting three years after the initial cliff. Following the grant, Ms. Cote beneficially owns 150,000 derivative securities and reported no ownership of, or transactions in, non-derivative common shares.
This award forms part of her employment package and aligns her long-term incentives with shareholder interests. Although the grant introduces potential dilution of roughly 150,000 shares, it does not involve any insider selling and therefore has minimal immediate market impact.
Vistagen Therapeutics (VTGN) has filed a Form 3 (Initial Statement of Beneficial Ownership) for Elissa S. Cote, who has been appointed as the company's Chief Corporate Development Officer. The filing date is June 28, 2025, with the triggering event occurring on June 23, 2025.
Key details from the filing:
- The reporting person currently owns no securities of the company, either direct or indirect
- No derivative securities (options, warrants, etc.) are reported as beneficially owned
- This is an individual filing, not a joint/group submission
- The filing address is listed as 343 Allerton Avenue, South San Francisco, CA 94080
This Form 3 filing is a standard regulatory requirement for new officers, directors, and 10% shareholders to disclose their initial ownership positions in the company's securities.
FAQ
What is the current stock price of Vistagen Therapeutics (VTGN)?
What is the market cap of Vistagen Therapeutics (VTGN)?
